Skip to content
LogiclyLogicly

Free for 14 days. No card to start.

Get started free

R97 Abnormal tumor markers

R97 is the ICD-10-CM code family for Abnormal tumor markers: 5 codes, none of which can lead a home health claim.

Codes in family

5

Can lead a claim

0

Cannot lead a claim

5

What CMS assigns to R97

None of the 5 codes is assigned a clinical group. None of the 5 is assigned a comorbidity subgroup. None can lead a claim.

Every code in R97

Descriptions are CDC’s FY2027 wording; where CMS’s grouper abbreviates one, its form is shown beneath.

CodeDescriptionPrimary positionClinical groupComorbidity subgroup
R97.0Elevated carcinoembryonic antigen [CEA]Cannot lead a claimPrincipal diagnosis not assigned to a clinical groupNoneNone
R97.1Elevated cancer antigen 125 [CA 125]Cannot lead a claimPrincipal diagnosis not assigned to a clinical groupNoneNone
R97.2 Elevated prostate specific antigen [PSA]
R97.20Elevated prostate specific antigen [PSA]Cannot lead a claimPrincipal diagnosis not assigned to a clinical groupNoneNone
R97.21Rising PSA following treatment for malignant neoplasm of prostateCMS: Rising PSA fol treatment for malignant neoplasm of prostateCannot lead a claimPrincipal diagnosis not assigned to a clinical groupNoneNone
R97.8Other abnormal tumor markersCannot lead a claimPrincipal diagnosis not assigned to a clinical groupNoneNone

Sources: CMS HH PPS Grouper Software (opens in a new tab) v07.2.26, effective 2026-10-01, for the clinical group, comorbidity subgroup, code-first conventions and primary-position flags; CDC NCHS ICD-10-CM FY2027 (opens in a new tab) code descriptions for the family title and code wording. This is the crosswalk Medicare runs a claim through. Grouping also depends on admission source, timing, the OASIS functional items and the rest of the diagnosis list.